En Español | Plain Text Version | Skip Navigation

You are here:  Home > Funding & Research > Research > Parkinson's Disease Research Web

Parkinson's Disease Research Web: Events in FY 2003

Skip secondary menu

Join our electronic mailing list

All FY2003 Events related to Parkinson's disease research have been categorized according to the following Sub-topics. Abstracts of each event have been included.

Program Announcements

Pathogenesis and Treatment of Dyskinesias in Parkinson's Disease (PAS-02-129)

With this Program Announcement, the National Institute of Neurological Disorders and Stroke (NINDS) invites research grant applications (R01) that address the development and treatment of dopamine-induced dyskinesias, a major complication of current pharmacotherapy of Parkinson's disease. The purpose of this initiative is to 1) support the study of the pathophysiologic basis of dopamine-induced dyskinesias; and 2) support the study of non- dopaminergic pharmacologic agents for the treatment of dopamine-induced dyskinesias.

Top

Basic and Translational Research on the Cognitive Sequelae of Parkinson's Disease (PAS-02-107)

Under this PA, the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), the National Institute on Deafness and Other Communication Disorders, and the National Institute of Mental Health (NIMH) invites research grant applications (R01) that address the underlying neurobiological mechanisms associated with the cognitive and linguistic sequelae of Parkinson's disease. A major goal of this PA is to begin a process where basic and clinical scientists from various disciplines can overcome barriers to cross-disciplinary research and examine all aspects of cognition in the context of the diagnosis and treatment of Parkinson's disease. The purpose of this initiative is to: 1) focus the attention of neuroscientists on the detrimental neurodegenerative processes that affect cognition and language in Parkinson's disease; 2) promote the interaction of cognitive neuroscientists and clinical scientists conducting research in Parkinson's disease patients; and 3) develop integrative research programs that advance our understanding of the substrates of cognitive function in health and in Parkinson's disease. Applications that demonstrate the establishment of collaborative research programs with researchers at existing Centers of Excellence for Parkinson's disease research are particularly encouraged

Top

Morris K. Udall Parkinson's Disease Research Centers of Excellence (PAR-03-004)

In response to continuing research progress and opportunity, and in recognition of continuing Congressional interest to intensify and to expand basic and clinical research in Parkinson's disease, The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Environmental Health Sciences (NIEHS) invite qualified investigators to submit grant applications for the establishment of Morris K. Udall Parkinson's Disease Research Centers of Excellence. The purpose of this Program Announcement (PA) is to encourage additional research opportunities and discoveries that will lead to improved diagnosis and treatment of patients with Parkinson's Disease and related neurodegenerative disorders, based on a better understanding of the fundamental cause(s) of the disease. It is expected that these Centers will form a consortium of investigators that will foster an environment that will enhance research effectiveness in a multi-disciplinary setting, utilizing specialized methods relevant to the study of these disorders.

Top

Cachexia: Research into Biobehavioral Management and Quality of Life (PA-01-109)

This Program Announcement (PA) solicits applications for investigator- initiated research related to the prevention and management of cachexia to improve the quality of life for these patients. Cachexia is a condition of severe malnutrition characterized by anorexia, weight loss and muscle wasting that occurs as a consequence of chronic conditions such as cystic fibrosis, cerebral palsy, cancer, AIDS, congestive heart failure, failure to thrive in older populations, end-stage organ failure, neurological degenerative diseases, chronic obstructive lung disease, chronic liver disease, and chronic renal disease. Cachexia has repeatedly been associated with adverse clinical outcomes, and increased morbidity and mortality.

Top

Requests for Applications (RFA)

Top

Notices

Requirements for Designation as an NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research (NOT-NS-03-021)

Many PD research centers may be interested in being designated as a Morris K. Udall Center of Excellence for Parkinson's Disease Research, including:

  • Currently-funded Udall Centers, interested in maintaining this designation pending review of their competing renewal
  • New centers that will be considered under NINDS-PA-03-004
  • Recently-funded P50 and P01 grantees that received funding prior to the release of NINDS-PAR-03-004

This notice outlines the requirements necessary to ensure that all interested PD research centers may be considered for Udall designation.

Top

NINDS Announces Budget Ceiling Increase for Clinical Research on Solicited Specialized Research Centers (NOT-NS-03-020)

NINDS has released three initiatives in the last five years to create centers (P50 and U54 mechanisms) to perform translational and clinical research in Parkinson's disease (http://grants.nih.gov/grants/guide/pa-files/PAR-03-004.html), stroke (http://grants.nih.gov/grants/guide/pa-files/PAS-01-092.html), and minority health (http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-00-001.html). Performance of high quality research involving patient-oriented research (http://www.nih.gov/news/crp/97report/execsum.htm) requires resources devoted to training personnel, ensuring appropriate inclusion and follow-up of subjects, monitoring patient safety, and coordinating activity among participating sites. In order to ensure that important patient-oriented projects proceed with adequate resources, NINDS announces that investigators submitting new applications for these programs may request annual direct costs up to $1,500,000.

Top

Availability of GCRC Resources for Long Term Follow Up of Participants in Gene Transfer Protocols (NOT-RR-04-005)

In 2002, three years after receiving retrovirally transduced stem cells, two subjects who were enrolled in a gene transfer research study developed T cell leukemia. These events highlighted the potential for serious adverse events to emerge long after the subject's active involvement in the study. Gene transfer research investigators must confront these risks in order to maximize the protection of human subjects who participate in gene transfer research protocols and to help advance understanding of the underlying mechanisms involved. To address these concerns, the FDA now recommends that all subjects enrolled in gene transfer studies be followed for 15 years after administration of the study agent.

Top

Call for Assay Proposals for the NINDS High Throughput Drug Screening Services Facility (NOT-NS-04-005)

The National Institute of Neurological Disorders and Stroke established a high throughput drug screening (HTS) facility at Southern Research Institute in Birmingham, Alabama in 2002. This facility was established to provide an opportunity for neurodegeneration researchers with robustand reproducible assays to have their assays tested against a collection of 100,000 compounds in a high throughput setting. The NINDS is now accepting proposals for new neurodegeneration-related assays to be adapted and screened at the HTS facility. The types of assays sought and instructions for applying to the program are provided in the notice.

Top

NINDS Administrative Supplements for the Sharing and Distribution of Mouse Genetic Models (NOT-NS-04-009)

The National Institute of Neurological Disorders and Stroke (NINDS) announces the reissue of an administrative supplement program designed to support and encourage the timely sharing of mouse genetic models (or other rodent genetic lines) included within the scope of currently funded NINDS research projects. The sharing of data, biomaterials and other unique research resources such as genetically modified mouse strains is an essential element in the rapid progress that has been made in the genetic analysis of neurological disorders and complex behavioral traits.

Top

Last updated February 09, 2005